Since KDM1 expression is upregulated in gliomas, because KDM1-mediated demethylation reduces p53 transactivation functions, blocking the KDM1 axis could have therapeutic implications for reducing glioma proliferation in WTp53 expressing gliomas. Here, TP53 is linked to central nervous system cancer.